• PRS10 PREVALENCE OF PULMONARY HYPERTENSION IN GERMANY–ESTIMATIONS BASED ON A TOP-DOWN APPROACH

    Nov 1, 2006, 00:00

  • PIN3 COST–EFFECTIVNESS ANALYSIS OF TONSILOPHARYNGITIS AND RHYNOPHARINGITIS ACCUTA, ANTIBIOTIC TREATMANT, SRBIJA, NIS REGION

    Nov 1, 2006, 00:00

  • PIN15 CHRONIC HEPATITIS B (CHB) MANAGEMENT COSTS IN SWEDEN

    Nov 1, 2006, 00:00

  • POS17 BASELINE CHARACTERISTICS OF FRENCH POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

    Nov 1, 2006, 00:00

  • PUK24 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q), OVERACTIVE BLADDER SHORT FORM QUESTIONNAIRE (OAB-Q SF), AND OAB ASSESSMENT TOOL (OAB-V8) IN 4 LANGUAGES

    Nov 1, 2006, 00:00

  • PAA6 VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE EVENTS- COMPARISON OF CICLESONIDE WITH FLUTICASONE PROPIONATE

    Nov 1, 2006, 00:00

  • SZ3 PREDICTORS OF GAF CHANGES IN AUSTRALIANS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONGACTING INJECTION (RLAI)- INTERIM RESULTS FROM THE E-STAR STUDY

    Nov 1, 2006, 00:00

  • Erratum

    Sep 1, 2006, 00:00

  • Eliciting Stated Preferences for Health-Technology Adoption Criteria Using Paired Comparisons and Recommendation Judgments

    Sep 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as a First-Line Treatment- A Comment

    Sep 1, 2006, 00:00

  • Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version

    Sep 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as a First-Line Treatment- A Response to Comment

    Sep 1, 2006, 00:00

  • Implantable or External Defibrillators for Individuals at Increased Risk of Cardiac Arrest- Where Cost-Effectiveness Hits Fiscal Reality

    Sep 1, 2006, 00:00

  • Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States

    Sep 1, 2006, 00:00

  • Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical Trials

    Sep 1, 2006, 00:00

  • A Dollar Is a Dollar Is a Dollar—or Is It?

    Sep 1, 2006, 00:00

  • Development of a Smiling Touchscreen Multimedia Program for HRQoL Assessment in Subjects with Varying Levels of Literacy

    Sep 1, 2006, 00:00

  • Analyses of Cost Data in Economic Evaluations Conducted Alongside Randomized Controlled Trials

    Sep 1, 2006, 00:00

  • Indirect Costs and Cost-Effectiveness Analysis

    Jul 1, 2006, 00:00

  • Are Australians Able to Access New Medicines on the Pharmaceutical Benefits Scheme in a More or Less Timely Manner? An Analysis of Pharmaceutical Benefits Advisory Committee Recommendations, 1999–2003

    Jul 1, 2006, 00:00

  • Probabilistic Analysis and Computationally Expensive Models- Necessary and Required?

    Jul 1, 2006, 00:00

  • An Economic Evaluation of Two Ototopical Treatments for Acute Otitis Media in Tympanostomy Tube Patients

    Jul 1, 2006, 00:00

  • Applying the Grid Computation in Long-Term Retrospective Health Insurance Data Analysis

    Jul 1, 2006, 00:00

  • Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?

    Jul 1, 2006, 00:00

  • Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population

    Jul 1, 2006, 00:00

  • Managing Meningococcal Disease in the United States- Hospital Case Characteristics and Costs by Age

    Jul 1, 2006, 00:00

  • Fraction of Nursing Home Admissions Attributable to Urinary Incontinence

    Jul 1, 2006, 00:00

  • Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses

    Jul 1, 2006, 00:00

  • Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data

    Jul 1, 2006, 00:00

  • Formulary Decision-Making Should Rely on the Best Available Evidence

    Jul 1, 2006, 00:00

  • POS14 HOME AUTOMATED TELEMANAGEMENT IN POST-HIP FRACTURE REHABILITATION

    May 1, 2006, 00:00

  • PNL27 THE EFFECT OF ADHERENCE TO ALZHEIMER'S DISEASE TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE

    May 1, 2006, 00:00

  • FP1 USE OF MEDICATION COVERAGE METHODOLOGY IN MEASUREMENT OF PATIENT COMPLIANCE WITH PHARMACOTHERAPY

    May 1, 2006, 00:00

  • PIN12 LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B

    May 1, 2006, 00:00

  • PPN2 IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY LOSS, AND DIRECT HEALTH CARE COSTS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2006, 00:00

  • PMH22 ANTIPSYCHOTIC POLYPHARMACY COSTS-A FIVE-STATE MEDICAID STUDY

    May 1, 2006, 00:00

  • PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS- AN EMPIRICAL ANALYSIS

    May 1, 2006, 00:00

  • PPN1 OPIOID ASSOCIATED ERECTILE DISFUNCTION IN CHRONIC PAIN PATIENTS

    May 1, 2006, 00:00

  • PRS3 COMBINATION THERAPY [LONG ACTING BETA AGONISTS (LABA) PLUS INHALED CORTICOSTEROIDS] VERSUS LABA ALONE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE- AN ECONOMIC ANALYSIS

    May 1, 2006, 00:00

  • PMH8 COST-EFFECTIVENESS OF VENLAFAXINE- A CANADIAN PERSPECTIVE

    May 1, 2006, 00:00

  • PMC14 PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FORA QALY- DO THEY VARY BY COUNTRY? HAVE THEY CHANGED OVERTIME?

    May 1, 2006, 00:00

  • PAR2 ACTIVE SAFETY SURVEILLANCE FORTU-HUO-CHI-SHENG-TANG- A CHINESE HERBAL PRODUCT USED IN TREATIN OSTEOARTHRITIS OF KNEE

    May 1, 2006, 00:00

  • ND2 EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF TRANSDERMAL FENTANYL AND TRANSDERMAL BUPRENORPHINE IN CANCERAND NON-CANCER PATIENTS IN GERMANY- RESULTS FROM A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PAR1 PRESCRIPTION FOR LONGER LIFE- A DIAGNOSIS OF OSTEOARTHRITIS?

    May 1, 2006, 00:00

  • PCV45 RELIABILITY AND VALIDITY OF TAIWAN VERSION OF TREATMENT-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR PATIENTS RECEIVING ORAL ANTICOAGULATION

    May 1, 2006, 00:00

  • PIN6 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS

    May 1, 2006, 00:00

  • PIN22 USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY

    May 1, 2006, 00:00

  • PIN23 A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS

    May 1, 2006, 00:00

  • PMC11 DEVELOPMENT OF A GLOBAL HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER- CALIBRATION TO THE UNITED KINGDOM AND NETHERLANDS

    May 1, 2006, 00:00

  • PGI15 PRIOR AUTHORIZATION AND THE APPROPRIATE PRESCRIBING OF TEGASEROD- A LOOK AT A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PIH10 THE TRANSLATION AND CULTURAL ADAPTATION OF AN ADOLESCENT SEXUAL BEHAVIOUR QUESTIONNAIRE

    May 1, 2006, 00:00

  • PMH36 VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES

    May 1, 2006, 00:00

  • PHP7 THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL- A GAME-THEORETIC ANALYSIS

    May 1, 2006, 00:00

  • PCN40 THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE- A REVIEW OF VALIDATED INSTRUMENTS CURRENTLY AVAILABLE

    May 1, 2006, 00:00

  • PDB3 EARLY HEALTH TECHNOLOGY ASSESSMENT- CONTINUOUS GLUCOSE MONITORING FOR THE MAINTENANCE OF GLYCEMIC CONTROL IN INSULIN-REQUIRING TYPE I DIABETES

    May 1, 2006, 00:00

  • PMH17 RESOURCE-USE AND COSTS ASSOCIATED WITH PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE

    May 1, 2006, 00:00

  • PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE + METFORMIN VERSUS NATEGLINIDE + METFORMIN IN TYPE 2 DIABETES PATIENTS WITH INADEQUATE GLYCEMIC CONTROL ON MONOTHERAPY- A FINNISH ANALYSIS

    May 1, 2006, 00:00

  • PMS3 COMPARISON OF HOSPITAL COST WITH DRG REIMBURSEMENT RATE IN PATIENTS WITH PERITROCHANTERIC FRACTURE ACCORDING TO SURGICAL METHODS

    May 1, 2006, 00:00

  • PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES- RESULTS FROM A COMPUTERIZED SIMULATION MODEL

    May 1, 2006, 00:00

  • PMS1 HEALTH TECHNOLOGY ASSESSMENT- EXTRACORPOREAL SHOCKWAVE THERAPY (ESWT) FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS

    May 1, 2006, 00:00

  • PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN

    May 1, 2006, 00:00

  • CV2 IMPACT OF VENTRICULAR ARRHYTHMIA ON MORTALITY, HEALTH CARE UTILIZATION AND COST IN HOSPITALIZED ACUTE MYOCARDIAL INFARCTION PATIENTS

    May 1, 2006, 00:00

  • PR6 VALIDATION OF THE WORK PRODUCTIVITY QUESTIONNAIRE- RESULTS OF THE MATRIX STUDY

    May 1, 2006, 00:00

  • PRS7 TREATING DOCTOR AND DIRECT COSTS OF HOSPITALIZATION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS

    May 1, 2006, 00:00

  • PAS2 DRUG ADVERSE EVENTS MODIFYTHE TREATMENT AND COMPLIANCE OF ASTHMA PATIENTS

    May 1, 2006, 00:00

  • PCV23 AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT) IN BRAZIL

    May 1, 2006, 00:00

  • PHP16 THE IMPACT OF THE PHARMACY AND THERAPEUTICS COMMITTEE ON THE PATIENTS'ACCESS TO PRESCRIPTION DRUGS IN THE SAUDI MINISTRY OF HEALTH- EXPLORATORY AND COMPARISON STUDY

    May 1, 2006, 00:00

  • PDB9 PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS

    May 1, 2006, 00:00

  • PNL17 ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES

    May 1, 2006, 00:00

  • PIH18 EXPLORATORY FACTOR ANALYSIS OF A 13 ITEM BPH PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE (BPH-PSTQ)

    May 1, 2006, 00:00

  • Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden

    May 1, 2006, 00:00

  • PMS2 THE COST-EFFECTIVENESS OF EXTRACORPOREAL SHOCK WAVE THERAPY FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS

    May 1, 2006, 00:00

  • PRS9 EVALUATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS INITIATING AN INHALED CORTICOSTEROID OR AN ANTICHOLINERGIC INA MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PCV21 COSTS OF DIAGNOSTIC PROCEDURES OF INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2006, 00:00

  • PHP11 PRESCRIPTION PATTERNS OF POTENTIALLY INAPPROPRIATE MEDICATIONS AMONG OLDER MEDICARE MANAGED CARE BENEFICIARIES

    May 1, 2006, 00:00

  • PNL25 FAILURE OF REGRESSION ADJUSTMENT AGAINST PROPENSITY SCORE MATCHING

    May 1, 2006, 00:00

  • PDB22 RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDY WITH PROPENSITY SCORE METHODS- CAN THEIR RESULTS CONVERGE?—A CASE STUDY IN ESTIMATING MARGINAL EFFECT OF INSULIN REGIMENS ON THE REDUCTION OF HEMOGLOBIN AIC AMONG PATIENTS WITH TYPE ...

    May 1, 2006, 00:00

  • PAS8 IMPROVING ASTHMA SELF-MANAGEMENT AND PATIENT OUTCOMES USING AN AUTOMATED PROGRAM

    May 1, 2006, 00:00

  • HP2 THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS IN AN EMPLOYED POPULATION

    May 1, 2006, 00:00

  • PUK7 FACTORS INFLUENCING EARLY NEPHROLOGY CARE PRIOR TO HEMODIALYSIS INITIATION AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE

    May 1, 2006, 00:00

  • AC3 DETERMINANTS OF NON-COMPLIANCE WITH BISPHOSPHONATE THERAPY IN WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS

    May 1, 2006, 00:00

  • PRS4 LIFETIME COSTS AND IMPACT ON LIFE EXPECTANCY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE U.S.- PROJECTIONS FROM A DECISION-ANALYTIC MODEL

    May 1, 2006, 00:00

  • PCN17 EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION

    May 1, 2006, 00:00

  • Linguistic Validation of the US Spanish Work Productivity and Activity Impairment Questionnaire, General Health Version

    May 1, 2006, 00:00

  • PGI18 A NEW APPROACH TO USING SELF-REPORTED UTILIZATION TO ESTIMATE COST ASSOCIATED WITH MILD, MODERATE, AND SEVERE GERD-RELATED SYMPTOMS

    May 1, 2006, 00:00

  • PAS12 TREATMENT PERSISTENCE AND COMPLIANCE WITH MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2006, 00:00

  • PCN24 DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT—AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL

    May 1, 2006, 00:00

  • PCV20 MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE

    May 1, 2006, 00:00

  • PCN25 REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY- RESULTS FROM A LARGE RETROSPECTIVE OBSERVATIONAL STUDY

    May 1, 2006, 00:00

  • PNL15 COST-OF-ILLNESS FOR ADULTS WITH PARTIAL EPILEPSY IN SWEDEN

    May 1, 2006, 00:00

  • PEY4 EVALUATION OF DIRECT MEDICAL COST OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN PATIENTS IN THE MEDICARE POPULATION

    May 1, 2006, 00:00

  • POS10 TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PATIENTS WITH PAGET'S DISEASE TREATED WITH RISENDRONATE

    May 1, 2006, 00:00

  • PCV37 SURVEY OF PHYSICIAN ATTITUDES AND PRACTICES IN LIPID LOWERING MANAGEMENT

    May 1, 2006, 00:00

  • PMC3 HOW MUCH DOES A DAY IN THE HOSPITAL COSTÏ

    May 1, 2006, 00:00

  • PMH40 ATYPICAL ANTIPSYCHOTIC COMPLIANCE AND PERSISTENCE AND ASSOCIATED HEALTH CARE UTILIZATION IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • POT3 COST OF HOSPITALIZATIONS FOR ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS PRE-AND POST-REPEAL OF THE UNIVERSAL HELMET LAW IN FLORIDA

    May 1, 2006, 00:00

  • PCV61 DETERMINANTS OF ADHERENCE TO STATINS INA MEDICAID MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PDB26 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—A METHODOLOGICAL COMPARISON USING A CLAIMS DATABASE

    May 1, 2006, 00:00

  • PIH3 COST-EFFECTIVENESS ANALYSIS OF ORAL PHARMACOLOGICAL TREATMENTS OF ERECTILE DYSFUNCTION

    May 1, 2006, 00:00

  • POS8 PRICE AND UTILIZATION OF OSTEOPOROSIS MEDICATIONS IN U.S. MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES- ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES

    May 1, 2006, 00:00

  • PDB20 BLOOD GLUCOSE MONITORING RECOMMENDATIONS AND PRACTICES IN PATIENTS WITH TYPE 2 DIABETES- A SURVEY OF HEALTH CARE PROFESSIONALSAND PATIENTS IN THE UK

    May 1, 2006, 00:00

  • PDB24 EFFECTS OF INDUCING CORRELATION AMONG CHOLESTEROL PARAMETERS ON OUTCOMES IN SIMULATION OF PHARMACEUTICAL EFFECTIVENESS

    May 1, 2006, 00:00

  • PCV7 A PROSPECTIVE STUDY EVALUATING STREPTOKINASE THERAPY ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH MYOCARDIAL INFARCTION AT A TERTIARY CARE REFERRAL HOSPITAL IN KERALA, INDIA

    May 1, 2006, 00:00

  • PRO4 PREVALENCE OF MEDICATION COMPLIANCE AND PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PDB17 MODELING THE COST-UTILITY OF REDUCED HYPOGLYCEMIA ANDWEIGHT GAIN AMONG TYPE 2 DIABETES PATIENTS NEWLY INITIATED ON BASAL INSULIN- A CASE STUDY OF DETEMIRAND NPH

    May 1, 2006, 00:00

  • PUK9 ESTIMATING A PREFERENCE-BASED INDEX FROM A CONDITION SPECIFIC MEASURE-THE KING'S HEALTH QUESTIONNAIRE

    May 1, 2006, 00:00

  • PCV6 MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES WITH EXTENDED-RELEASE NIACIN/LOVASTATIN VERSUS SIMVASTATIN/EZETIMIBE COMBINATION THERAPY IN AT-RISK PATIENTS

    May 1, 2006, 00:00

  • PNL20 HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT

    May 1, 2006, 00:00

  • The Future of Health Economic Modeling- Have We Gone Too Far or Not Far Enough?

    May 1, 2006, 00:00

  • POB3 COST-UTILITY ANALYSIS OF RIMONABANT IN THE TREATMENT OF OBESITY

    May 1, 2006, 00:00

  • PG12 DOSE-RESPONSE RELATION OF INTERFERON-ALPHA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B- META-ANALYSIS AND META-REGRESSION OF RANDOMIZED TRIALS

    May 1, 2006, 00:00

  • Economic Evaluation in Health Care- The Point of View of Informed Physicians

    May 1, 2006, 00:00

  • PDB29 IMPACT OF TYPE OF PHARMACY (CHAIN VERSUS INDEPENDENT) ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PCV26 PRESCRIBING PATTERNS FOR ANTIHYPERTENSIVE DRUGS AFTERTHE PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) IN REGION EMILIA ROMAGNA (RER), ITALY

    May 1, 2006, 00:00

  • PCN34 VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE- DATA FROM CAPSURE

    May 1, 2006, 00:00

  • PNL6 EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE AGONISTS FORTHETREATMENT OF RESTLESS LEGS SYNDROME

    May 1, 2006, 00:00

  • PCV54 DETERMINANTS OF TREATMENT PERSISTENCE INA GERMAN HYPERTENSIVE POPULATION

    May 1, 2006, 00:00

  • HI1 ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES- 2000-2002

    May 1, 2006, 00:00

  • ID2 OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG SWITCHING IN PATIENTS WITH SERIOUS CANDIDA INFECTIONS

    May 1, 2006, 00:00

  • HP3 DETERMINANTS OF GENERIC ENTRY IN LAST DECADE

    May 1, 2006, 00:00

  • POT1 INCIDENCE AND ECONOMIC IMPACT ANALYSIS OF HYPONATREMIA IN HOSPITALIZED PATIENTS

    May 1, 2006, 00:00

  • PHP12 MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN RAJASTHAN, INDIA

    May 1, 2006, 00:00

  • HI4 IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES-THE CASE OF ATYPICAL ANTIPSYCHOTICS

    May 1, 2006, 00:00

  • PCV12 ASSESSMENT OF THE EFFECTS OF ROFECOXIB, CELECOXIB AND NAPROXEN ON BLOOD PRESSURE AND CARDIOVASCULAR RISK- A RETROSPECTIVE CHART REVIEW STUDY

    May 1, 2006, 00:00

  • PIN14 DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO

    May 1, 2006, 00:00

  • PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS

    May 1, 2006, 00:00

  • PMC19 EVALUATING THE STRENGTH OF EVIDENCE OF CHANGE- A QUALIFIED CHANGE VS SIMPLE DIFFERENCE APPROACH TO QUALITY OF LIFE RATINGS

    May 1, 2006, 00:00

  • PRO2 SELF-REPORTED HEALTH STATUS PREDICTORS OF MEDICATION ADHERENCE IN OLDER ADULTS WITH CHRONIC DISEASES

    May 1, 2006, 00:00

  • PHP21 CALCULATION OF LORENZ CONCENTRATION CURVES AND GINI COEFFICIENT OF HEALTH EXPENDITURES IN HUNGARY

    May 1, 2006, 00:00

  • Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients

    May 1, 2006, 00:00

  • MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003

    May 1, 2006, 00:00

  • PNL5 ASSESSING ABSOLUTE REDUCTIONS IN CLINICAL EFFECT- A MODEL FOR COMPARING THE COST-EFFECTIVENESS OF DISEASE MODIFYING DRUGS (DMDS) UTILIZED IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)

    May 1, 2006, 00:00

  • PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C- THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN

    May 1, 2006, 00:00

  • PMH21 HEALTH CARE RESOURCE UTILIZATION AND COST OF BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC SYMPTOMS

    May 1, 2006, 00:00

  • PGI10 COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE

    May 1, 2006, 00:00

  • PCN21 4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY- EARLY HEALTH TECHNOLOGY ASSESSMENT

    May 1, 2006, 00:00

  • PCV38 INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE HYPERTENSION

    May 1, 2006, 00:00

  • PDB38 A LITERATURE REVIEW OF TREATMENT SATISFACTION, ADHERENCE AND QOL INSTRUMENTS USED IN TYPE I AND 2 DIABETES

    May 1, 2006, 00:00

  • PMC12 THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS- A STRUCTURED REVIEW OF THE LITERATURE

    May 1, 2006, 00:00

  • PAS1 LEAVING AGAINST MEDICAL ADVICE (LAMA) IN ASTHMA EXACERBATION- CHARACTERISTICS AND DETERMINANTS OF LEAVERS

    May 1, 2006, 00:00

  • PCN1 ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS

    May 1, 2006, 00:00

  • PMH3 AUSTRALIAN SCHIZOPHRENIC PATIENTS TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)- INTERIM RESULTS FROM THE E-STAR STUDY

    May 1, 2006, 00:00

  • PCV65 PATIENT ADHERENCE WITH ANTIDIABETIC, ANTIHYPERTENSIVE, AND LIPID-LOWERING MEDICATIONS- EVALUATION OF VETERANS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PHP1 A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION

    May 1, 2006, 00:00

  • PIH12 SURVEY ASSESSMENT OF TREATMENT COMPLIANCE AND MEDICATION TAKING BEHAVIOR IN BENIGN PROSTATIC HYPERPLASIA

    May 1, 2006, 00:00

  • PR3 RACIAL DIFFERENCES IN PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE ASSESSMENT

    May 1, 2006, 00:00

  • PHM2 ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA

    May 1, 2006, 00:00

  • PSK3 “HEALTH BENEFIT LIMITS” LIMIT TREATMENT OF PSORIASIS AND OTHER DERMATOLOGICAL CONDITIONS

    May 1, 2006, 00:00

  • PSM2 EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS

    May 1, 2006, 00:00

  • PAR7 MODELLING OF THE COST-EFFECTIVENESS OF RITUXIMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY

    May 1, 2006, 00:00

  • PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA

    May 1, 2006, 00:00

  • PNL23 CONTROLLING SELECTION BIAS ON CONTINUOUS VARIABLES

    May 1, 2006, 00:00

  • PMC16 GENERAL HEALTH STATUS AND PATIENT SATISFACTION- ARE THEY MUTUALLY EXCLUSIVE OR CORRELATED OUTCOMES?

    May 1, 2006, 00:00

  • PDB33 THE RELATIONSHIP BETWEEN HEALTH RELATED QUALITY OF LIFE (HRQOL)AND PAIN RESPONSE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)

    May 1, 2006, 00:00

  • PMH31 LIKELIHOOD OF EMPLOYMENT TERMINATION FOR EMPLOYEES WITH BIPOLAR DISORDER TREATED WITH DIFFERENT PSYCHOTROPIC MEDICATIONS

    May 1, 2006, 00:00

  • PAS7 COMPUTERIZED DECISION SUPPORT FOR ASTHMA MANAGEMENT

    May 1, 2006, 00:00

  • PCN43 A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23- DESCRIPTIVE HEALTH RELATED QUALITY OF LIFE INSTRUMENT USED IN BREAST CANCER

    May 1, 2006, 00:00

  • PNL28 STUDYING DISCONTINUATION, SWITCHING, AND AUGMENTATION USING COMPETING RISK METHODS

    May 1, 2006, 00:00

  • POB5 THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED QUALITY OF LIFE AMONG US ADULTS

    May 1, 2006, 00:00

  • PIH16 WHAT EXPECTATIONS DO MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) HAVE FOR TREATMENT?

    May 1, 2006, 00:00

  • PMC4 THE LEVEL OF AWARENESS OFTMC PHYSICIANS ON THE PRICES OF COMMONLY PRESCRIBED MEDICATIONS AND DIAGNOSTIC PROCEDURES AND ITS EFFECT ON THEIR PRESCRIBING PREFERENCES

    May 1, 2006, 00:00

  • PIN16 CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS- A PREVALENT COST ISSUE

    May 1, 2006, 00:00

  • HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PCV1 USING ANTI-COAGULANTS AS PROPHYLAXIS FOR DVT/PE

    May 1, 2006, 00:00

  • PUK8 ONE SOLUTION TO THREE PROBLEMS

    May 1, 2006, 00:00

  • PG14 COMPARATIVE EFFICACY OF LAMIVUDINE WITH ADEFOVIR IN PATIENTS WITH HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B- DIRECT AND INDIRECT META-ANALYSIS

    May 1, 2006, 00:00

  • PDB32 A SYSTEMATIC REVIEW OF ADHERENCE WITH DIABETES TREATMENT AND THE IMPACT OF NON-ADHERENCE ON HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PUK6 EVALUATING THE OUTCOME AND COST ASSOCIATED WITH ATAMSULOSIN REAUTHORIZATION PROGRAM

    May 1, 2006, 00:00

  • PCV36 RATE OF LOW-DENSITY LIPOPROTEIN (LDL) GOAL ATTAINMENT WITH LIPID LOWERING THERAPIES AT A LI PID CLINIC IN A PUBLIC HOSPITAL OF HONG KONG—POSSIBLE ROLE OF A CLINICAL PHARMACY SERVICE

    May 1, 2006, 00:00

  • PCN22 THE EFFECT OF EFFICIENCY OF ACCESS TO CARE

    May 1, 2006, 00:00

  • PIN17 A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM

    May 1, 2006, 00:00

  • PMH27 THE IMPACT OF PRESCRIBING OFF-LABEL MOOD STABILIZERS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PMH14 BURDEN OF ILLNESS OF ALZHEIMER'S PATIENTS IN COMMERCIAL MANAGED CARE

    May 1, 2006, 00:00

  • PCN19 COLONOSCOPYAND FLEXIBLE SIGMOIDOSCOPY- A MICROCOSTING STUDY EVALUATING DIAGNOSTIC PROCEDURAL COSTS IN AN OUTPATIENT ENDOSCOPY CLINIC

    May 1, 2006, 00:00

  • PUK10 PSYCHOMETRIC PROPERTIES OF THE KING'S HEALTH QUESTIONNAIRES SYSTEMATIC CRITICAL APPRISAL OF THE LITERATURE

    May 1, 2006, 00:00

  • PHP13 ENHANCING THE SAFETY OF OTC MEDICATION USE FOR HISPANIC CONSUMERS WITH BILINGUAL LABELS

    May 1, 2006, 00:00

  • What Decision-Makers Want and What They Have Been Getting

    May 1, 2006, 00:00

  • PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA

    May 1, 2006, 00:00

  • PDB14 MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAICAND LIPID TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PCN44 IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER

    May 1, 2006, 00:00

  • POB8 IMPACT OF ABDOMINAL OBESITY ON QUALITY OF LIFE

    May 1, 2006, 00:00

  • PCV39 PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION- AN APPLICATION OF LATENT CLASS MODELS

    May 1, 2006, 00:00

  • PCN38 PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP

    May 1, 2006, 00:00

  • PAR8 USING MABTHERA IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN- RESULTS OF COST-EFFECTIVENESS DATA BASED ON MICRO-SIMULATION

    May 1, 2006, 00:00

  • PCV17 DECISION ANALYSIS TO COMPARE THE COST-EFFECTIVENESS OF THE STATINS AVAILABLE BY PRESCRIPTION VERSUS OVER THE COUNTER BASED FROM A SOCIETAL PERSPECTIVE

    May 1, 2006, 00:00

  • PIN18 HOSPITAL LENGTH-OF-STAYAND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS

    May 1, 2006, 00:00

  • PMC8 AN INTERACTIVE ECONOMIC MODEL FOR VACUUM ASSISTED CLOSURE THERAPY

    May 1, 2006, 00:00

  • PAR16 CAN OSTEOARTHRITIS PATIENTS EVALUATE TRADEOFFS BETWEEN NSAID RISKS AND BENEFITS?

    May 1, 2006, 00:00

  • PPN5 ADVANCES IN PAIN MEASUREMENT- ITEM RESPONSE THEORY (IRT) BASED METHODS AND THE PAIN IMPACT QUESTIONNAIRE (PIQ-6)

    May 1, 2006, 00:00

  • PIH9 TEXAS COMMUNITY PHARMACISTS'WILLINGNESS TO ACCEPT PHARMACIST INITIATED EMERGENCY CONTRACEPTION

    May 1, 2006, 00:00

  • PCV49 PATIENT ADHERENCE TO AHA GUIDELINES PRE-AND POST AMI

    May 1, 2006, 00:00

  • PRS1 SURVIVAL AMONG COPD PATIENTS USING FLUTICASONE/SALMETEROL IN COMBINATION VERSUS OTHER INHALED STEROIDS AND BRONCHDIALATORS ALONE

    May 1, 2006, 00:00

  • PCV56 PERSISTENCE WITH NEWLY-INITIATED EXTENDED-RELEASE NIACIN VERSUS OTHER LIPID MODIFYING DRUG CLASSES IN CLINICAL PRACTICE

    May 1, 2006, 00:00

  • PAR13 A PROSPECTIVE STUDY COMPARING DRUG UTILIZATION PATTERNS AND COST OF TREATMENT OF PATIENTS FOR RHEUMATOID ARTHRITIS IN KERALA, INDIA

    May 1, 2006, 00:00

  • PCV22 INPATIENT MANAGEMENT OF TRANSMURAL AND SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION (AMI)- DIFFERENCES IN RESOURCE USE AND COST

    May 1, 2006, 00:00

  • PMH5 INCIDENT DIABETES ASSOCIATED WITH USE OF SECOND-GENERATION ANTIPSYCHOTIC (SGA) THERAPY-AN EVALUATION OF THE IMPACT OF DOSE AND TREATMENT INDICATION

    May 1, 2006, 00:00

  • PR1 A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D PREFERENCE BASED SCORE FROM COMMONLY REPORTED SF-12 STATISTICS

    May 1, 2006, 00:00

  • POS9 TRENDS IN THE CLINICAL MANAGEMENT OF FRAGILE FRACTURE BEFORE AND AFTERTHE NEW HEDIS OSTEOPOROSIS MANAGEMENT MEASURE IN A MEDICARE POPULATION

    May 1, 2006, 00:00

  • POS4 COMPARATIVE ANALYSIS OF HEALTH INSURANCE COST OF MEDIAL FEMORAL NECK FRACTURES WITH AND WITHOUT COMPLICATIONS ON A 2 YEARS FOLLOW UP

    May 1, 2006, 00:00

  • PGI16 TRENDS OF GASTRIC ACID-SUPPRESSIVE DRUG USE IN THE GENERAL PRACTICE OF UK FROM 1995 TO 2005

    May 1, 2006, 00:00

  • PMC18 THE PROLABELS DATABASE- A NEW ON-LINE TOOL TO EXPLORE THE WORDING AND TYPES OF PRO INCLUDED IN APPROVED MEDICINAL PRODUCTS LABELS

    May 1, 2006, 00:00

  • PUK3 ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER

    May 1, 2006, 00:00

  • PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN- RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL

    May 1, 2006, 00:00

  • PR4 CONVERTING THE SCORES OF A CLINICAL INSTRUMENT FOR MEASURING PAIN TO A PREFERENCE BASED ONE

    May 1, 2006, 00:00

  • PCN37 ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G

    May 1, 2006, 00:00

  • PG15 COMPARING THE COST-EFFECTIVENESS OF THE INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV)- A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS

    May 1, 2006, 00:00

  • PCV4 A NATIONAL STUDY PREDICTING THE INFLUENCE OF PAYMENT SOURCES ON THE THIAZIDE DIURETICS UTILIZATION FOR HYPERTENSION

    May 1, 2006, 00:00

  • PEY2 PREVALENCE AND DESCRIPTION OF TREATMENT WITH INTRAOCULAR PRESSURE LOWERING TOPICAL MEDICATIONS IN CONTINENTAL FRANCE

    May 1, 2006, 00:00

  • PDB21 ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN FRANCE- EVIDENCE FROM PRIMARY CARE PHYSICIANS

    May 1, 2006, 00:00

  • HP4 PRESCRIPTION DRUG INSURANCE AND ITS EFFECT ON UTILIZATION AND HEALTH OF THE ELDERLY

    May 1, 2006, 00:00

  • CV1 INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES

    May 1, 2006, 00:00

  • PDB35 TOPIRAMATE TREATMENT IMPROVES QUALITY OF LIFE (QOL)AND NERVE FUNCTION IN PATIENTS WITH DIABETIC NEUROPATHY (DN)

    May 1, 2006, 00:00

  • PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS- RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY

    May 1, 2006, 00:00

  • POS7 CHANGES IN THE IMPAIRED ABILITYTO WORK IN PATIENTS UNDER 60 WITH MEDIAL FEMORAL NECK FRACTURE DURING 3 YEARS FOLLOW UP

    May 1, 2006, 00:00

  • PCV15 ATRIAL VERSUS DUAL CHAMBER PACING IN SINUS NODE DISEASE

    May 1, 2006, 00:00

  • PEY3 THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING INTRAOCULAR LENSES ON AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH CATARACT SURGERY

    May 1, 2006, 00:00

  • POT2 FATIGUE IN THE U.S. WORKFORCE- PREVALENCE AND COST OF LOST PRODUCTIVE WORK TIME

    May 1, 2006, 00:00

  • PDB23 EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), AND THE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PUK13 GENERIC VS. DISEASE-SPECIFIC SATISFACTION MEASURES- SELECTING A SATISFACTION MEASURE FOR OVERACTIVE BLADDER STUDIES

    May 1, 2006, 00:00

  • PIH7 APPROPRIATE MEDICATION PRESCRIBING FORTHE ELDERLY- PHYSICIAN CONFIDENCE AND KNOWLEDGE

    May 1, 2006, 00:00

  • PMH43 RAMIFICATIONS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PCN36 DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER- QUALITATIVE STUDY

    May 1, 2006, 00:00

  • PMC9 THE USE OF QUINTILE ANALYSIS ASA MEASURE OF DISEASE SEVERITY- A COMPARISON WITHIN AND ACROSS DISEASES

    May 1, 2006, 00:00

  • FP4 NATIONAL ESTIMATES AND ASSOCIATED FACTORS OF ANTIPSYCHOTIC USE IN AMBULATORY CARE FROM 1996 TO 2003

    May 1, 2006, 00:00

  • UR3 FACTORS ASSOCIATED WITH CARE SEEKING FOR OVERACTIVE BLADDER SYMPTOMS

    May 1, 2006, 00:00

  • PNL30 COMPARISON OF HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN MULTIPLE SCLEROSIS- A REVIEW

    May 1, 2006, 00:00

  • PDB37/DBI- PATIENT-REPORTED UTILITIES/DISUTILITIES ASSOCIATED WITH TREATMENTS FOR TYPE 2 DIABETES

    May 1, 2006, 00:00

  • ND4 IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY- RESULTS FROM TWO U.S. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIALS

    May 1, 2006, 00:00

  • PCV28 ECONOMIC EVALUATION OF AN INTERDISCIPLINARY APPROACH TO HEART FAILURE MANAGEMENT

    May 1, 2006, 00:00

  • PDB36 EQ-5D IN TYPE 2 DIABETES- RELATIONSHIPS WITH QUALITY OF LIFE AND COMORBID CONDITIONS

    May 1, 2006, 00:00

  • PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS

    May 1, 2006, 00:00

  • PRS5 RESOURCE USE AND COST OF HEALTHCARE SERVICES AMONG PATIENTS NEWLY DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS- EVIDENCE FROM A LARGE STATE MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PMH1 CRITERIA FOR IDENTIFYING PATIENTS WITH DEMENTIA AND PREVALENCE ESTIMATES OF DEMENTIA AMONG INDIANA MEDICAID RECIPIENTS

    May 1, 2006, 00:00

  • ND3 A DESCRIPTION OF OFFICE VISIT RATESAND PRESCRIPTION USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PCN31 A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES

    May 1, 2006, 00:00

  • PMH6 NEW-ONSET DIABETES MELLITUS ASSOCIATED WITH USE OF ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIC PATIENTS IN TAIWAN

    May 1, 2006, 00:00

  • PDB1 RETROSPECTIVE STUDY OF INSULIN GLARGINE USE IN PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PDB28 DEVELOPMENT OF NEW INDICES OF GLYCEMIC CONTROL IN PATIENTS WITH DIABETES USING DIGITAL SIGNAL PROCESSING

    May 1, 2006, 00:00

  • PCN46 ONLINE REPORTING OFTOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY

    May 1, 2006, 00:00

  • PDB8 ECONOMIC IMPACT OF AUGMENTATION THERAPY IN TYPE 2 DIABETES PATIENTS INITIATED ON SULFONYLUREAS- A RETROSPECTIVE COHORT ANALYSIS

    May 1, 2006, 00:00

  • PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS

    May 1, 2006, 00:00

  • PIH5 A SYSTEMATIC REVIEW OF ATROPHIC VAGINITIS TREATMENT, DURATION OF THERAPY, AND HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PCV66 A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE HEART FAILURE

    May 1, 2006, 00:00

  • PMH29 ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATION CLINICAL PRIOR AUTHORIZATION PROGRAM'S IMPACT ON PRESCRIPTION DRUG UTILIZATION AND COSTS

    May 1, 2006, 00:00

  • PHP27 CLUSTER ANALYSIS OF STATE MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PCN4 RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER

    May 1, 2006, 00:00

  • PMH37 COMPARING ADHERENCE AND PERSISTENCE WITH ANTIPSYCHOTIC THERAPY AMONG PATIENTS WITH BIPOLAR DISORDER

    May 1, 2006, 00:00

  • ND1 THE INDIRECT COST BURDEN OF MIGRAINE AMONG SEVERAL LARGE U.S. EMPLOYERS

    May 1, 2006, 00:00

  • CS4 FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    May 1, 2006, 00:00

  • PIH13 COMPLIANCE WITH PRESCRIBED ONCE A DAY PLACEBO IN ADOLESCENT HEALTHYVOLUNTEERS

    May 1, 2006, 00:00

  • PRO3 EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE WITH PEGYLATED INTERFERON THERAPY- A PROPENSITY SCORE MATCHED RETROSPECTIVE COHORT ANALYSIS

    May 1, 2006, 00:00

  • PMC17 MULTI-METHOD QUALITATIVE APPROACH TO DEVELOP COMPREHENSIVE PATIENT-REPORTED OUTCOME MEASURES- AN EXAMPLE FROM DENTAL CARE

    May 1, 2006, 00:00

  • PNL3 HOSPITAL LENGTH OF STAY ASSOCIATED WITH ANTICONVULSANT UTILIZATION BY PATIENTS WITH SEIZURE DISORDERS IN THE U.S.

    May 1, 2006, 00:00

  • FP3 AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN AMCP DOSSIER SUBMISSIONS 2002-2005

    May 1, 2006, 00:00

  • PMH41 PREDICTORS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PIH6 MEDICAL RESOURCE UTILIZATION IN DIAGNOSED PREMATURE EJACULATION PATIENTS

    May 1, 2006, 00:00

  • FP2 COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING PROGRAM- A MODEL EVALUATING THE RELATIVE CLINICAL AND ECONOMIC IMPACT IN COMMERCIAL VS. SENIOR MEMBER POPULATIONS

    May 1, 2006, 00:00

  • PMH33 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS PRESCRIBED ANTIPSYCHOTIC (AP) MONOTHERAPY IN TEXAS MEDICAID

    May 1, 2006, 00:00

  • PGI21 ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT- A CROSS SECTIONAL EVALUATION IN BRAZIL

    May 1, 2006, 00:00

  • PCV51 OUTPATIENT DISCONTINUATION AND RESTARTING OF POST-MYOCARDIAL INFARCTION BETA-BLOCKERTHERAPY

    May 1, 2006, 00:00

  • PCN16 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS- A MEDICARE PERSPECTIVE

    May 1, 2006, 00:00

  • PHP6 BENEFICIARIES' OUT-OF-POCKET COSTS UNDER THE MEDICARE PRESCRIPTION DRUG BENEFIT- EVIDENCE FROM MEDICARE DISCOUNT DRUG CARD CLAIMS DATA

    May 1, 2006, 00:00

  • PUK5 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

    May 1, 2006, 00:00

  • PMC24 BAYESIAN ESTIMATION OF COST-EFFECTIVENESS ADJUSTED FOR REAL WORLD CONSIDERING STATISTICAL ERRORS IN CLINICAL TRIALS

    May 1, 2006, 00:00

  • PGI14 COST-UTILITY OF A MODALITY OF “C” VIRUS HEPATITIS TREATMENT IN PATIENTS THAT DO NOT RESPOND TO INTERFERON PLUS RIBAVIRIN IN MEXICO

    May 1, 2006, 00:00

  • PMH12 AN ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTIC FOR BIPOLAR DISORDER IN THE NC MEDICAID PROGRAM

    May 1, 2006, 00:00

  • CS3 THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS

    May 1, 2006, 00:00

  • PMH47 THE MISSION IS REMISSION–HEALTH ECONOMIC CONSEQUENCES OF ACHIEVING REMISSION WITH ANTIDEPRESSANT TREATMENT FOR DEPRESSION

    May 1, 2006, 00:00

  • CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA

    May 1, 2006, 00:00

  • PMH19 ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PEY6 REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE

    May 1, 2006, 00:00

  • PNL26 EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS TO CONSIDER UNOBSERVED VARIABLE BIAS- AN APPLICATION OF SENSITIVITY ANALYSIS

    May 1, 2006, 00:00

  • PRS2 EVALUATION OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG COPD PATIENTS USING INHALED CORTICOSTEROIDS ORANTICHOLINERGIC AGENTS IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PGI12 COST-UTILITY ANALYSIS OFTEGASEROD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

    May 1, 2006, 00:00

  • PCV68 BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL AMONG MEN PRESCRIBED SILDENAFIL CITRATE

    May 1, 2006, 00:00

  • PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS A NEW TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS IN GERMANY

    May 1, 2006, 00:00

  • PCN9 ECONOMIC EVALUATION OFANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

    May 1, 2006, 00:00

  • PMH23 HEALTH CARE RESOURCE UTILIZATION PRE/POST RISPERIDONE LONG-ACTING INJECTABLE TREATMENT INITIATION IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PMH10 COST AND EFFECTIVENESS OF SWITCHING FROM RISPERIDONE TO OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PCV13 CLOPIDOGREL THERAPY AND HEALTH CARE COSTS FOLLOWING AN ACUTE CORONARY SYNDROME EVENT

    May 1, 2006, 00:00

  • CN1 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS- A PRIVATE PAYER PERSPECTIVE

    May 1, 2006, 00:00

  • PMH34 DETERMINANTS IN ANTIDEPRESSANT TREATMENT SELECTION FOLLOWING THE INTRODUCTION OF DULOXETINE

    May 1, 2006, 00:00

  • CN3 COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004

    May 1, 2006, 00:00

  • PMC23 NOT ALL PATIENTS ARE AVERAGE-THE IMPORTANCE OF RECOGNISING PATIENT HETEROGENEITY

    May 1, 2006, 00:00

  • PMH45 DURATION OF ANTIPSYCHOTIC SWITCHING PROCESS IN THE NATURALISTIC TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PAS9 THE PERFORMANCE OF BOOTSTRAPPING IN DISCRETE CHOICE MODELS

    May 1, 2006, 00:00

  • PHP25 HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PHARMACEUTICAL CARE- EVALUATING PHARMACIST'S KNOWLEDGE, UNDERSTANDING AND PERCEIVED BARRIERS IN PHARMACY PRACTICE

    May 1, 2006, 00:00

  • POB1 ASSOCIATION BETWEEN BMI AND HEALTH CARE EXPENDITURES USING THE 2002 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • PCN14 COST-EFFECTIVENESS OFTAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER

    May 1, 2006, 00:00

  • PCV30 TREND ANALYSIS OF PRICE AND UTILIZATION OF STATIN DRUGS IN U.S. MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • HI3 THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES

    May 1, 2006, 00:00

  • AC4 OCCURRENCE OF THROMBOCYTOPENIA AFTER ORTHOPEDIC SURGERIES IN PATIENTS TREATED WITH FONDAPARINUX, DALTEPARIN, ENOXAPARIN OR UNFRACTIONATED HEPARIN

    May 1, 2006, 00:00

  • PCV42 PREDICTING HIGH COSTS IN CALIFORNIA MEDICAID PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)

    May 1, 2006, 00:00

  • Bringing Health Economic Modeling to the 21st Century

    May 1, 2006, 00:00

  • PCV52 MEDICATION ADHERENCE- PREDICTORS AND IMPACT ON HOSPITALIZATION RISK

    May 1, 2006, 00:00

  • PHP22 PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD

    May 1, 2006, 00:00

  • POS3 BUDGET IMPACT ANALYSIS OF BISPHOSPHONATES FOR FRACTURES IN POSTMENOPAUSAL WOMEN

    May 1, 2006, 00:00

  • PHP26 DEVELOPING A MEASURE OF PATIENT EMPOWERMENT TO BE APPLIED IN THE GENERAL COMMUNITY

    May 1, 2006, 00:00

  • PAS13 ASSOCIATION OF MEDICATION ADHERENCE WITH WORKPLACE PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA

    May 1, 2006, 00:00

  • PHP3 IMPACT OF CONSUMER-DIRECTED HEALTH PLAN ON PHARMACY UTILIZATION

    May 1, 2006, 00:00

  • PCV44 THE CASE OF LI PI D-LOWERING THERAPY- A COMPARISON OF ADHERENCE MEASUREMENT METHODOLOGIES USING ADMINISTRATIVE CLAIMS DATA

    May 1, 2006, 00:00

  • PUK4 ELEVATED INTACT PARATHYROID HORMONE LEVELSAND HEALTH CARE COSTS AND UTILIZATION- RETROSPECTIVE COHORT OF PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2006, 00:00

  • PMH24 INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS- EFFECTS ON THE TREATMENT FOR SCHIZOPHRENIA IN A MEDI-CAL POPULATION

    May 1, 2006, 00:00

  • PIH17 DEVELOPMENT OF A PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE FOR BENIGN PROSTATIC HYPERPLASIA (BPH-PSTQ)

    May 1, 2006, 00:00

  • PG19 COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C

    May 1, 2006, 00:00

  • HE2 ESTIMATING OUT-OF-POCKET PHARMACEUTICAL EXPENDITURES UNDERTHE NEW MEDICARE DRUG LAW FOR PATIENTS WITH MENTAL DISORDERS—AN ANALYSIS OF CLAIMS DATA FROM RETIREE MEDICAL PLANS

    May 1, 2006, 00:00

  • PMH13 AN ECONOMIC COST ANALYSIS OF ATYPICAL ANTIPSYCHOTIC SINGLE TREATMENT FOR BIPOLAR DISORDER IN A MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PNL32 EVALUATION OF THE IMPACT OF AN EMPLOYEE WORKSITE DISEASE MANAGEMENT PROGRAM FOR MIGRAINEURS ON WORK PRODUCTIVITY

    May 1, 2006, 00:00

  • PCV8 OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS TREATED WITH NESIRITIDE

    May 1, 2006, 00:00

  • RS4 AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH CARE UTILIZATION AND USE OF SALMETEROL AMONG SUBJECTS WITH ASTHMA

    May 1, 2006, 00:00

  • PSU2 THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL INTERVENTIONS IN THE UK

    May 1, 2006, 00:00

  • PAR4 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN THE UK

    May 1, 2006, 00:00

  • PRS6 TOBACCO SMOKING AND DIRECT COSTS OF TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS

    May 1, 2006, 00:00

  • PMH46 HEALTH-RELATED QUALITY-OF-LIFE MEASURED BY EQ-5D IN PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE

    May 1, 2006, 00:00

  • PMC15 INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE

    May 1, 2006, 00:00

  • PDB27 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—COMPARISON OF RESULTS WITH AND WITHOUT PROPENSITY SCORING

    May 1, 2006, 00:00

  • PDB39 DIABETIC PATIENTS' PREFERENCE FOR INHALED INSULIN

    May 1, 2006, 00:00

  • PHP18 IMPACT OF STEPS (SAFE, THERAPEUTIC AND ECONOMIC PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING COSTS OF STATINS

    May 1, 2006, 00:00

  • PIN2 COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS- INFORMATION FROM THE SIDESTEP STUDY

    May 1, 2006, 00:00

  • PCV64 THE LEVEL AND LONG-TERM DYNAMICS OF THE QUALITY OF LIFE AS PREDICTORS OF ADHERENCE TO ROUTINE HYPERTENSION MANAGEMENT

    May 1, 2006, 00:00

  • PHP19 COST SAVINGS ASSOCIATED WITH TABLET SPLITTING PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2006, 00:00

  • PPN3 THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS- COST EFFECTS IN THE CALIFORNIA WORKERS' COMPENSATION SYSTEM

    May 1, 2006, 00:00

  • PCN8 COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN

    May 1, 2006, 00:00

  • PCV67 PREDICTORS OF HIGH BLOOD PRESSURE KNOWLEDGE IN HYPERTENSIVE PATIENTS

    May 1, 2006, 00:00

  • PRO5 PHYSICIAN IMPRESSIONSAND USES OF PATIENT-REPORTED OUTCOMES DATA

    May 1, 2006, 00:00

  • PAR20 BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT PREFERENCES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2006, 00:00

  • PCV11 EVALUATION OF A MAIL-BASED WARFARIN (COUMADIN®) PATIENT EDUCATION INITIATIVE IN A MANAGED CARE SETTING

    May 1, 2006, 00:00

  • PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER

    May 1, 2006, 00:00

  • PAR10 COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS- A PAN-EUROPEAN ANALYSIS

    May 1, 2006, 00:00

  • PMH16 HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES

    May 1, 2006, 00:00

  • PCV9 CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO STATINS IN A MEDICAID POPULATION

    May 1, 2006, 00:00

  • PSK5 TREATMENT PATTERNS IN PATIENTS WITH SEVERE PSORIASIS

    May 1, 2006, 00:00

  • PCV60 IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS ON TOTAL PHARMACY AND MEDICAL COSTS

    May 1, 2006, 00:00

  • PCV32 DRUG PRICE AND UTILIZATION OF ACE INHIBITORS IN US MEDICAID POPULATION

    May 1, 2006, 00:00

  • PMH38 ADHERENCE LEVELS AND DIFFERENTIAL USE OF MENTAL HEALTH SERVICES IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PMH4 META-ANALYSIS OF SNRIS, SSRIS, AND TCAS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER USING REMISSION AS THE CLINICAL OUTCOME

    May 1, 2006, 00:00

  • PCN42 PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS- DATA FROM CAPSURE™

    May 1, 2006, 00:00

  • PCV29 ANALYSES FOR PRICE AND UTILIZATION OF CALCIUM CHANNEL BLOCKERS IN US MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PRO1 RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PMC25 MEASURING SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES- NEW SOLUTIONS TO OLD PROBLEMS

    May 1, 2006, 00:00

  • POS11 THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING

    May 1, 2006, 00:00

  • PHP9 SUMMARY OF THE FIRST YEAR OF A DISEASE MANAGEMENT PROGRAM IN PATIENTS WITH BLEEDING DISORDERS

    May 1, 2006, 00:00

  • PUK1 PREVALENCE OF NEUROGENIC BLADDER IN PATIENTS WITH VARIOUS NEUROLOGIC DISORDERS IN THE UNITED STATES

    May 1, 2006, 00:00

  • POB6 SELF-IMAGE SCALE- A PRAGMATIC EVALUATION

    May 1, 2006, 00:00

  • CS2 ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS- AN ERADICABLE GLOBAL HEALTH PROBLEM

    May 1, 2006, 00:00

  • PCV31 DRUG PRICE AND UTILIZATION OF BETA BLOCKERS IN US MEDICAID PROGRAMS

    May 1, 2006, 00:00

  • PIN4 ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS- QUANTIFERON®-TB GOLD IN-TUBE (QFT-GIT) VERSUS TUBERCULIN SKIN TESTING (TST)

    May 1, 2006, 00:00

  • UR4 THE COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES FORABNORMAL UTERINE BLEEDING

    May 1, 2006, 00:00

  • PMC2 HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF AROMATASE INHIBITORS

    May 1, 2006, 00:00

  • POB9 EFFECT OF RIMONABANT ON QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS

    May 1, 2006, 00:00

  • PIN21 USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION

    May 1, 2006, 00:00

  • HI2 CLINICAL IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER

    May 1, 2006, 00:00

  • PMH28 SELECTION OF ATYPICAL ANTIPSYCHOTIC MONO-THERAPY FOR PATIENTS WITH BIPOLAR DISORDER- AN ANALYSIS OF A MEDICAID POPULATION

    May 1, 2006, 00:00

  • PAR12 A COST-EFFICACY ANALYSIS MODEL FOR ANTI-TNF AGENTS IN PSORIATIC ARTHRITIS

    May 1, 2006, 00:00

  • PR7 RISK INDICATORS FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION OUTCOMES IN HEMOPHILIA PATIENTS-THE HEMOPHILIA COST AND IMPACT OF DISEASE STUDY-PART V

    May 1, 2006, 00:00

  • PGI13 A COST UTILITY ANALYSIS OF PEGUINTERFERON ALFA 2B (I2KD) (PEG2B)VERSUS PEGUINTERFERON ALFA 2A (40KD) (PEG2A) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN BRAZIL

    May 1, 2006, 00:00

  • PAR11 COST-EFFECTIVENESS ANALYSIS FOR TREATMENTS IN ANKYLOSING SPONDYLITIS

    May 1, 2006, 00:00

  • PDB6 FACTORS ASSOCIATED WITH DIABETES CONTROL INA LATINO POPULATION USING A HEALTH BEHAVIOR MODEL APPROACH

    May 1, 2006, 00:00

  • DB3 QUALITY OF LIFE IN PEOPLE WITH AND AT RISK FOR TYPE 2 DIABETES- FINDINGS FROM THE STUDYTO HELP IMPROVE EARLY EVALUATION AND MANAGEMENT OF RISK FACTORS LEADING TO DIABETES (SHIELD)

    May 1, 2006, 00:00

  • PMH2 META-ANALYSIS OF ANTIDEPRESSANTTREATMENT EFFECTS IN PATIENTS AFTER STROKE

    May 1, 2006, 00:00

  • PGI22 WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS- CROHN'S DISEASE PATIENTS'WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS

    May 1, 2006, 00:00

  • PIN13 COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY

    May 1, 2006, 00:00

  • PDB31 ASSOCIATION BETWEEN RACE AND MEDICATION ADHERENCE IN TYPE 2 DIABETES MEDICAID ENROLLEES

    May 1, 2006, 00:00

  • RS3 LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY OBSTRUCTION (FEV,) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE- A POPULATION BASED RECORD LINKAGE STUDY IN A LARGE UK POPULATION

    May 1, 2006, 00:00

  • PNL2 RESTLESS LEGS SYNDROME- IDENTIFICATION OF TREATED PATIENTS IN A LARGE CLAIMS DATABASE

    May 1, 2006, 00:00

  • PMC21 DEVELOPMENT AND VALIDATION OF A SCALE TO MEASURE PATIENTS'TRUST IN PHARMACISTS IN SINGAPORE

    May 1, 2006, 00:00

  • PIH1 THE EXCESS PREVALENCE OF COMORBIDITIES ASSOCIATED WITH ERECTILE DYSFUNCTION IN A LARGE STATE MEDICAID PROGRAM

    May 1, 2006, 00:00

  • POS1 ONE-AND TWO-YEAR PERSISTENT USE OF BISPHOSPHONATES REDUCES THE RISK OF OSTEOPOROTIC FRACTURES IN DAILY PRACTICE

    May 1, 2006, 00:00

  • PCV5 PATIENT RISK ASSESSMENT AND ENGAGEMENT IN PRIMARY CARE MANAGEMENT OF CARDIOVASCULAR RISK

    May 1, 2006, 00:00

  • PMH25 LEARNING FROM NICE TECHNOLOGY ASSESSMENTS- A CASE STUDY OF ITS RECENT APPRAISAL OF ADHD TREATMENT STRATEGIES

    May 1, 2006, 00:00

  • PCV55 ADHERENCE MEASURES- SO MANYTO CHOOSE FROM, WHAT IS THE DIFFERENCE?

    May 1, 2006, 00:00

  • PCV63 ASSOCIATION OFANTIHYPERTENSIVE MEDICATION CLASS WITH BLOOD PRESSURE CONTROL AND PERSISTENCE ON MONOTHERAPY

    May 1, 2006, 00:00

  • PMH15 BURDEN OF ILLNESS AMONG PATIENTS WITH ALZHEIMER'S DISEASE IN A COMMERCIALLY-INSURED POPULATION

    May 1, 2006, 00:00

  • PCV27 THE IMPACT OF DOSE INCREASE ON THE COST-EFFECTIVENESS OF STATINS

    May 1, 2006, 00:00

  • HP1 RECENT POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT HAVE REDUCED COST DRAMATICALLY

    May 1, 2006, 00:00

  • PCV41 PROVISION OF DIET/NUTRITION AND EXERCISE COUNSELING FOR PATIENTS WITH DYSLIPIDEMIA BY AMBULATORY CARE PHYSICIANS IN THE UNITED STATES

    May 1, 2006, 00:00

  • CN2 MAMMOGRAPHY SCREENING USE AMONG MEDICARE BENEFICIARIES AGE 65 OR OLDER

    May 1, 2006, 00:00

  • CV4 MANAGING CONGESTIVE HEART FAILURE- COHORT ANALYSIS OF USE AND COST OF HOSPITAL, EMERGENCY DEPARTMENT AND OBSERVATION UNIT CARE OVER TWELVE MONTHS

    May 1, 2006, 00:00

  • PMH35 THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY

    May 1, 2006, 00:00

  • Substantial Returns to Health-Care Spending- But Do We Spend Too Little or Too Much?

    May 1, 2006, 00:00

  • PR2 QUANTIFYING PATIENTS' RISK-BENEFIT TRADEOFF PREFERENCES- A CONCEPTUAL AND EMPIRICAL COMPARISON OF METHODS

    May 1, 2006, 00:00

  • PDB30 COSTS AND ADHERENCE ASSOCIATED WITH LONG TERM USE OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS

    May 1, 2006, 00:00

  • PCN28 REVIEW OF ECONOMIC APPRAISALS OF CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER

    May 1, 2006, 00:00

  • PHP4 OUT-OF-POCKET PRICE OF OUTPATIENT MEDICATIONS IN THE UNITED STATES

    May 1, 2006, 00:00

  • ID4 COMPLIANCE WITH ANTIBIOTIC TREATMENT GUIDELINES IN MEDICARE MANAGED CARE PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN AMBULATORY SETTINGS

    May 1, 2006, 00:00

  • PIH4 ECONOMIC BURDEN OF ABNORMAL UTERINE BLEEDING- ARE THERE PIECES MISSING?

    May 1, 2006, 00:00

  • PDB18 ECONOMIC BURDEN OF DIABETES ATTRIBUTABLE TO OVERWEIGHT AND OBESITY AMONG U.S. ADULTS

    May 1, 2006, 00:00

  • PAS4 ECONOMETRIC MODELING IN CHRONIC ASTHMA ALLOWS COMPARISONS BETWEEN DIFFERENT THERAPY GROUPS

    May 1, 2006, 00:00

  • PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS- CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?

    May 1, 2006, 00:00

  • PGI11 ECONOMIC BURDEN OF ENDOSCOPY-RELATED INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS

    May 1, 2006, 00:00

  • DB4 STRESS AND COPING STRATEGIES ASSOCIATED WITH PHYSICAL AND MENTAL HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PIN9 ECONOMIC EVALUATION FORTHE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR—ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO

    May 1, 2006, 00:00

  • PCV47 AN APPROACH TO GENERALIZE CLINICAL TRIAL RESULTS TO NON-STUDY POPULATIONS FOR COST-EFFECTIVENESS EVALUATIONS—THE CASE OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS)

    May 1, 2006, 00:00

  • AC2 THE PREVALENCE OF SUBJECTIVELY EXPERIENCED ADVERSE DRUG REACTIONS. A NATIONWIDE SURVEY IN SWEDEN

    May 1, 2006, 00:00

  • PCN41 EQ-5D IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)- ASSESSMENT OF VALIDITY AND RESPONSIVENESS

    May 1, 2006, 00:00

  • PAR18 HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OSTEOARTHRITIS- A SYSTEMATIC REVIEW TO ASSESS THE MEASUREMENT PROPERTIES OFTHEWOMAC (WESTERN ONTARIO MCMASTER OSTEOARTHRITIS INDEX) FOR DISCRIMINATIVE AND EVALUATIVE RESEARCH

    May 1, 2006, 00:00

  • PMH9 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF ACUTE MANIA

    May 1, 2006, 00:00

  • PCN6 HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCERAND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD)

    May 1, 2006, 00:00

  • PG16 COST-EFFECTIVENESS OF SCREENING PRISON POPULATION OF MARYLAND CORRECTIONAL FACILITIES FOR HEPATITIS C

    May 1, 2006, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165 (current)
  • 166
  • 167
  • 168
  • 169
  • 170
  • »